Tuoxin Pharmaceutical

Tuoxin Pharmaceutical Group Joint-stock Co., Ltd. (hereinafter referred to as the Group) is a high-tech enterprise integrating the R&D, production and sales of chemical synthesis and biological fermentation nucleoside (acid) APIs and pharmaceutical intermediates, with strong strength in the development and production of nucleoside (acid) APIs and pharmaceutical intermediates in China.
The Group has advantages in the R&D field of nucleoside (acid) APIs and pharmaceutical intermediates in China, such as early start, large scale, and complete variety, and has formed a relatively complete ladder-type product chain from basic products to high-end products. The Group has established an efficient catalytic synthesis reaction technology platform, a nucleoside fermentation technology platform, and a biotransformation semi-synthesis technology platform; and has formed several series of nucleoside (acid) products including pyrimidine series, purine series, nucleotide series, and nucleoside series, including APIs and pharmaceutical intermediates such as citicoline sodium, ribavirin, inosine, cytosine, 5-fluorocytosine, and cytidine; mainly covering the fields of antiviral, anti-tumor, and nervous system drugs.